TaiMed Biologics (ROCO:4147) FCF Margin %: 6.14% (As of Dec. 2025)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics FCF Margin %?

TaiMed Biologics ROCO:4147 55 FCF Margin % is 6.14% as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued). Among 949 Biotechnology companies, TaiMed Biologics ranks better than 92.73% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TaiMed Biologics's Free Cash Flow for the three months ended in Dec. 2025 was NT$9.2 Mil. TaiMed Biologics's Revenue for the three months ended in Dec. 2025 was NT$149.9 Mil. Therefore, TaiMed Biologics's FCF Margin % for the quarter that ended in Dec. 2025 was 6.14%.

As of today, TaiMed Biologics's current FCF Yield % is 0.90%.

The historical rank and industry rank for TaiMed Biologics's FCF Margin % or its related term are showing as below:

ROCO:4147' s FCF Margin % Range Over the Past 10 Years
Min: -9463.94   Med: -94.76   Max: 27.54
Current: 27.54

During the past 13 years, the highest FCF Margin % of TaiMed Biologics was 27.54%. The lowest was -9463.94%. And the median was -94.76%.

ROCO:4147's FCF Margin % is ranked better than
92.73% of 949 companies
in the Biotechnology industry
Industry Median: -82.65 vs ROCO:4147: 27.54

TaiMed Biologics FCF Margin % Related Terms

TaiMed Biologics FCF Margin % Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics FCF Margin % Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.38 -108.34 -6.46 -65.38 27.54

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -348.78 23.71 1.60 78.01 6.14

ROCO:4147 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, TaiMed Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiMed Biologics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's FCF Margin % falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TaiMed Biologics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=168.376/611.35
=27.54 %

TaiMed Biologics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=9.202/149.897
=6.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 6.14% mean?
TaiMed Biologics (ROCO:4147) has a FCF Margin % of 6.14% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #69 out of 949 companies in the Biotechnology industry, placing it in the top 7.3%.
Is TaiMed Biologics' FCF Margin % too high?
TaiMed Biologics' current FCF Margin % is 6.14%. Based on the distribution chart, TaiMed Biologics ranks #69 out of 949 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #69 out of 949 companies for FCF Margin %. This places TaiMed Biologics in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current FCF Margin % is 6.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current FCF Margin % is 6.14%. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current FCF Margin % is 6.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • FCF Margin %: 6.14%
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value